Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
This is the Phase 3 dose typically reached during weeks 9 through 12 of the standard escalation protocol
Obesity and obstructive sleep apnea-hypopnea syndrome
Off-label use and lack of clinical evidence The primary concern with microdosing GLP-1 RAs is the lack of scientific evidence
FDA approves new drug treatment for chronic weight management, first since 2014, Food and Drug Administration (2021) Once-weekly semaglutide in adults with overweight or obesity, New England Journal of Medicine (2021) Updates about Wegovy, Novo Nordisk (2024) Medications containing semaglutide marketed for type 2 diabetes or weight loss, FDA (2024) Drug shortages, Food and Drug Administration (2024) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity & Metabolism (2022) FDA approves Lillys Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes, Lilly Investors (2022) FDA approves new medication for chronic weight management, Food and Drug Administration (2023) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
